PFIZER INC

PFE 10-K · FY 2025
API behind this page

PFE FY 2025 request

Playground key active
Request URL /api/financials?ticker=PFE&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue (FY) — — —
Show Product Lines breakouts
Product 51,663 53,816 -4.0%
Product · Collaborative Arrangement 150 175 -14.3%
Royalty 1,650 1,423 +16.0%
Royalty · Collaborative Arrangement 1,130 923 +22.4%
Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer 9,266 8,388 +10.5%
Show Product Lines breakouts
Total Alliance revenues [Member] 9,266 8,388 +10.5%
Show Type Of Arrangement breakouts
Collaborative Arrangement 9,266 8,388 +10.5%
Revenue 62,579 63,627 -1.6%
Show Product Lines breakouts
Abrysvo [Member] · Biopharma [Member] 1,033 755 +36.8%
Adcetris [Member] · Biopharma [Member] 907 1,089 -16.7%
All other Hospital [Member] · Biopharma [Member] 4,030 4,167 -3.3%
All other Oncology [Member] · Biopharma [Member] 1,127 1,122 +0.4%
All other Primary Care [Member] · Biopharma [Member] 2,860 2,991 -4.4%
All other Specialty Care [Member] · Biopharma [Member] 1,588 1,489 +6.6%
Aromasin [Member] · Biopharma [Member] 450 347 +29.7%
Bosulif [Member] · Biopharma [Member] 611 645 -5.3%
Braftovi/Mektovi [Member] · Biopharma [Member] 716 607 +18.0%
Cibinqo [Member] · Biopharma [Member] 284 215 +32.1%
Comirnaty [Member] · Biopharma [Member] 4,367 5,353 -18.4%
Cresemba [Member] · Biopharma [Member] 349 281 +24.2%
Eliquis [Member] · Biopharma [Member] 7,961 7,366 +8.1%
Elrexfio [Member] · Biopharma [Member] 304 133 +128.6%
Enbrel (Outside the U.S. and Canada) [Member] · Biopharma [Member] 627 690 -9.1%
Excluding Comirnaty and Paxlovid [Member] · Biopharma [Member] 54,470 51,331 +6.1%
FSME-IMMUN/TicoVac [Member] · Biopharma [Member] 319 280 +13.9%
Genotropin [Member] · Biopharma [Member] 446 470 -5.1%
Ibrance [Member] · Biopharma [Member] 4,122 4,367 -5.6%
Inflectra [Member] · Biopharma [Member] 646 509 +26.9%
Inlyta [Member] · Biopharma [Member] 923 978 -5.6%
Lorbrena [Member] · Biopharma [Member] 1,023 731 +39.9%
Nurtec ODT/Vydura [Member] · Biopharma [Member] 1,424 1,263 +12.7%
Octagam [Member] · Biopharma [Member] 418 509 -17.9%
Oncology Biosimilars [Member] · Biopharma [Member] 1,301 1,037 +25.5%
Orgovyx [Member] · Biopharma [Member] 421 201 +109.5%
Padcev [Member] · Biopharma [Member] 1,940 1,588 +22.2%
Paxlovid [Member] · Biopharma [Member] 2,362 5,716 -58.7%
Pfizer CentreOne [Member] 1,338 1,146 +16.8%
Pfizer Ignite [Member] 41 82 -50.0%
Prevnar Family [Member] · Biopharma [Member] 6,494 6,411 +1.3%
Sulperazon (Outside the U.S. and Canada) [Member] · Biopharma [Member] 653 637 +2.5%
Talzenna [Member] · Biopharma [Member] 182 117 +55.6%
Tivdak [Member] · Biopharma [Member] 147 131 +12.2%
Tukysa [Member] · Biopharma [Member] 463 480 -3.5%
Vyndaqel Family [Member] · Biopharma [Member] 6,380 5,451 +17.0%
Xeljanz [Member] · Biopharma [Member] 1,087 1,168 -6.9%
Xtandi [Member] · Biopharma [Member] 2,194 2,039 +7.6%
Zavicefta (Outside the U.S. and Canada) [Member] · Biopharma [Member] 638 586 +8.9%
Zithromax [Member] · Biopharma [Member] 399 480 -16.9%
Show Business Segments breakouts
Biopharma [Member] 61,199 62,400 -1.9%
Biopharma [Member] · International Commercial Division 24,491 24,068 +1.8%
Biopharma [Member] · Oncology [Member] 16,834 15,612 +7.8%
Biopharma [Member] · Operating Segments 61,199 62,400 -1.9%
Biopharma [Member] · Primary Care [Member] 26,820 30,135 -11.0%
Biopharma [Member] · Specialty Care [Member] 17,546 16,652 +5.4%
Biopharma [Member] · U.S. Commercial Division 36,708 38,332 -4.2%
Show Geography breakouts
Developed Markets [Member] 16,188 16,057 +0.8%
Emerging Markets [Member] 9,313 8,879 +4.9%
US 37,078 38,691 -4.2%
Show Consolidation Items breakouts
Corporate Non Segment 1,380 1,228 +12.4%
Show Equity Method Investment Nonconsolidated Investee breakouts
ViiV [Member] 9,824 8,971 +9.5%
Show Type Of Arrangement breakouts
Collaborative Arrangement 10,546 9,486 +11.2%
Cost of Revenue 16,067 17,851 -10.0%
Show Business Segments breakouts
Biopharma [Member] 13,505 14,997 -9.9%
Show Type Of Arrangement breakouts
Collaborative Arrangement 2,181 2,901 -24.8%
Selling, General & Administrative 13,794 14,730 -6.4%
Show Business Segments breakouts
Biopharma [Member] 9,637 10,210 -5.6%
Show Type Of Arrangement breakouts
Collaborative Arrangement 324 335 -3.3%
Research And Development Expense Excluding Acquired In Process Cost 10,437 10,822 -3.6%
Show Business Segments breakouts
Biopharma [Member] 9,183 9,532 -3.7%
Research And Development Asset Acquired Other Than Through Business Combination Written Off 1,613 108 +1393.5%
Show Business Segments breakouts
Biopharma [Member] 113 108 +4.6%
Show Counterparty Name breakouts
3SBio [Member] · In-Licensing Agreement Option [Member] 1.35 — —
Amortization Of Intangible Assets Not Associated With Single Function 4,874 5,286 -7.8%
Restructuring Charges And Acquisition Related Costs 1,550 2,419 -35.9%
Other Non-Operating Income (Expense) 6,724 4,388 +53.2%
Show Business Segments breakouts
Biopharma [Member] -581 -416 -39.7%
Income Before Taxes 7,520 8,023 -6.3%
Show Business Segments breakouts
Biopharma [Member] 29,342 27,969 +4.9%
Biopharma [Member] · Operating Segments 29,342 27,969 +4.9%
Show Consolidation Items breakouts
Corporate Non Segment -8,199 -7,213 -13.7%
Material Reconciling Items · Acquisition-Related Items [Member] -1,285 -1,938 +33.7%
Material Reconciling Items · Amortization of Intangible Assets [Member] -4,874 -5,286 +7.8%
Material Reconciling Items · Certain Significant Items [Member] -7,464 -5,510 -35.5%
Income Tax Expense (Benefit) -266 -28 -850.0%
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest 7,787 8,051 -3.3%
Show Equity Method Investment Nonconsolidated Investee breakouts
ViiV [Member] 4,277 3,062 +39.7%
Income Loss From Discontinued Operations Net Of Tax 25 11 +127.3%
Net Income 7,812 8,062 -3.1%
Show Equity Components breakouts
Noncontrolling Interest 41 31 +32.3%
Parent 7,771 8,031 -3.2%
Retained Earnings 7,771 8,031 -3.2%
Show Equity Method Investment Nonconsolidated Investee breakouts
ViiV [Member] 4,277 3,062 +39.7%
Net Income Loss Attributable To Noncontrolling Interest 41 31 +32.3%
Net Income 7,771 8,031 -3.2%
Show Equity Method Investment Nonconsolidated Investee breakouts
ViiV [Member] 4,277 3,062 +39.7%
Income Loss From Continuing Operations Per Basic Share 1.37 1.42 -3.5%
EPS (Basic) 1.37 1.42 -3.5%
Income Loss From Continuing Operations Per Diluted Share 1.36 1.41 -3.5%
EPS (Diluted) 1.36 1.41 -3.5%
Wtd Avg Shares (Basic) 5,683 5,664 +0.3%
Wtd Avg Shares (Diluted) 5,713 5,700 +0.2%
Cost of Revenue (FY) — — —
Show Equity Method Investment Nonconsolidated Investee breakouts
ViiV [Member] -1,637 -1,360 -20.4%
Gross Profit (FY) — — —
Show Equity Method Investment Nonconsolidated Investee breakouts
ViiV [Member] 8,187 7,611 +7.6%
Interest Income -603 -545 -10.6%
Comprehensive Income 7,544 8,149 -7.4%
Net Income Loss Available To Common Stockholders Basic 7,771 8,031 -3.2%
Interest Expense 2,671 3,091 -13.6%

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash & Cash Equivalents 1,142 1,043 +9.5%
Accounts Receivable 11,874 11,463 +3.6%
Inventory 10,654 10,851 -1.8%
Other Tax Assets Current 3,967 3,314 +19.7%
Other Assets Current 2,808 4,253 -34.0%
Total Current Assets 42,898 50,358 -14.8%
Show Equity Method Investment Nonconsolidated Investee breakouts
ViiV [Member] 4,991 4,338 +15.1%
Non-Current Assets
Property, Plant & Equipment 19,317 18,393 +5.0%
Show Geography breakouts
Developed Markets [Member] 8,180 7,187 +13.8%
Emerging Markets [Member] 1,457 1,458 -0.1%
US 9,680 9,748 -0.7%
Goodwill 71,264 68,527 +4.0%
Deferred Tax Assets Net And Other Tax Assets Noncurrent 9,699 8,662 +12.0%
Other Non-Current Assets 9,631 9,817 -1.9%
Total Assets 208,160 213,396 -2.5%
Show Equity Method Investment Nonconsolidated Investee breakouts
ViiV [Member] 8,288 7,561 +9.6%
Operating Lease Right-of-Use Assets 2,213 2,289 -3.3%
Intangible Assets 31,510 35,848 -12.1%
Show Finite Lived Intangible Assets By Major Class breakouts
Developed Technology Rights 30,458 34,353 -11.3%
Licensing Agreements and Other [Member] 1,052 1,210 -13.1%
Other Assets
Other Short Term Investments 12,454 19,434 -35.9%
Other Long Term Investments 1,621 2,228 -27.2%
Intangible Assets Net Excluding Goodwill 53,731 55,411 -3.0%
Current Liabilities
Debt Current 3,154 6,946 -54.6%
Accounts Payable 5,240 5,633 -7.0%
Dividends Payable Current 2,445 2,437 +0.3%
Taxes Payable Current 3,103 2,910 +6.6%
Employee Related Liabilities Current 3,610 3,838 -5.9%
Deferred Revenue (Current) 784 1,511 -48.1%
Show Product Lines breakouts
Paxlovid and Comirnaty [Member] · Government and Government Sponsored [Member] 689 1.4 +49114.3%
Other Liabilities Current 18,648 19,720 -5.4%
Show Product Lines breakouts
Comirnaty [Member] · BioNTech [Member] 911 1.3 +69976.9%
Total Current Liabilities 36,984 42,995 -14.0%
Show Equity Method Investment Nonconsolidated Investee breakouts
ViiV [Member] 4,714 4,280 +10.1%
Current Portion of Long-Term Debt 2,997 3,747 -20.0%
Show Long-Term Debt Type breakouts
Unsecured Debt 2,997 3,747 -20.0%
Non-Current Liabilities
Long-Term Debt 61,641 57,405 +7.4%
Show Long-Term Debt Type breakouts
Unsecured Debt 61,641 57,405 +7.4%
Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent 2,041 2,115 -3.5%
Show Retirement Plan Type breakouts
Other Postretirement Benefit Plans Defined Benefit 75 74 +1.4%
Pension Plans Defined Benefit · Foreign Plan 1,334 1,364 -2.2%
Pension Plans Defined Benefit · US 632 678 -6.8%
Deferred Tax Liabilities 2,401 2,122 +13.1%
Liability For Uncertain Tax Positions Noncurrent 3,591 6,112 -41.2%
Other Non-Current Liabilities 14,725 14,150 +4.1%
Total Liabilities 121,385 124,899 -2.8%
Show Equity Method Investment Nonconsolidated Investee breakouts
ViiV [Member] 10,449 10,485 -0.3%
Long-Term Debt (Q) — — —
Show Derivative Risk breakouts
Foreign Currency Long-Term Debt [Member] 879 777 +13.1%
Operating Lease Liabilities 2,291 2,286 +0.2%
Contract With Customer Liability Noncurrent (Q) — — —
Show Product Lines breakouts
Paxlovid and Comirnaty [Member] · Government and Government Sponsored [Member] 826 785 +5.2%
Other Liabilities
Minority Interest 299 294 +1.7%
Stockholders' Equity
Common Stock 481 480 +0.2%
Additional Paid-In Capital 94,469 93,603 +0.9%
Treasury Stock Common Value -115,015 -114,763 -0.2%
Retained Earnings 114,610 116,725 -1.8%
Accumulated Other Comprehensive Income -8,069 -7,842 -2.9%
Total Stockholders' Equity 86,476 88,203 -2.0%
Show Equity Method Investment Nonconsolidated Investee breakouts
ViiV [Member] -2,161 -2,924 +26.1%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 86,775 88,497 -1.9%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment Net Prior Service Cost Credit 75 191 -60.7%
Accumulated Gain Loss Net Cash Flow Hedge Parent -321 57 -663.2%
Accumulated Net Unrealized Investment Gain Loss -28 -106 +73.6%
Accumulated Other Comprehensive Income -8,069 -7,842 -2.9%
Accumulated Translation Adjustment -7,796 -7,984 +2.4%
Additional Paid In Capital 94,469 93,603 +0.9%
Common Stock 481 480 +0.2%
Noncontrolling Interest 299 294 +1.7%
Parent 86,476 88,203 -2.0%
Retained Earnings 114,610 116,725 -1.8%
Treasury Stock Common -115,015 -114,763 -0.2%
Total Liabilities & Equity 208,160 213,396 -2.5%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Depreciation & Amortization 6,592 7,013 -6.0%
Show Business Segments breakouts
Biopharma [Member] · Operating Segments 1,379 1,360 +1.4%
Show Consolidation Items breakouts
Corporate Non Segment 305 340 -10.3%
Material Reconciling Items · Acquisition-Related Items [Member] -4 12 -133.3%
Material Reconciling Items · Amortization of Intangible Assets [Member] 4,874 5,286 -7.8%
Material Reconciling Items · Certain Significant Items [Member] 38 14 +171.4%
Asset Write Offs And Asset Impairment Charges 5,270 4,242 +24.2%
Deferred Income Taxes -2,133 -2,102 -1.5%
Stock-Based Compensation 799 877 -8.9%
Pension And Other Postretirement Benefit Contributions Net Of Pension And Other Postretirement Benefit Expense -786 -12 -6450.0%
Inventory Write Down (FY) — — —
Show Income Statement Location breakouts
Cost Of Sales 33 — —
Other Non-Cash Items -470 -2,260 +79.2%
Change in Accounts Receivable -263 -109 -141.3%
Change in Inventory 561 -854 +165.7%
Increase Decrease In Other Operating Assets 1,289 3,380 -61.9%
Increase Decrease In Accounts Payable Trade -469 -1,023 +54.2%
Increase Decrease In Other Operating Liabilities -3,667 -3,115 -17.7%
Increase Decrease In Accrued Taxes Payable -2,805 -1,345 -108.6%
Net Cash from Operations 11,704 12,744 -8.2%
Investing Activities
Capital Expenditures -2,629 -2,909 +9.6%
Payments To Acquire Short Term Investments -14,356 -10,133 -41.7%
Proceeds From Sale Maturity And Collection Of Shortterm Investments 17,959 4,128 +335.1%
Payments For Proceeds From Short Term Investments With Original Maturities Of Three Months Or Less -2,675 3,136 -185.3%
Payments To Acquire Marketable Securities -294 -180 -63.3%
Proceeds From Sale Maturity And Collection Of Longterm Investments 1,095 1,570 -30.3%
Proceeds From Sale Of Equity Method Investments 6,311 7,040 -10.4%
Payments To Acquire Businesses Net Of Cash Acquired -6,927 — —
Other Investing Activities 165 2 +8150.0%
Net Cash from Investing -1,351 2,652 -150.9%
Right Of Use Asset Obtained In Exchange For Operating Lease Liability 288 283 +1.8%
Financing Activities
Repayments Of Short Term Debt -2,199 -11,226 +80.4%
Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less -796 -2,590 +69.3%
Proceeds From Issuance Of Long Term Debt 9,678 — —
Repayments Of Long Term Debt -6,757 -2,250 -200.3%
Payments Of Ordinary Dividends -9,771 -9,512 -2.7%
Proceeds From Payments For Other Financing Activities -458 -469 +2.3%
Net Cash from Financing -10,304 -17,140 +39.9%
Supplemental
Income Taxes Paid 4,688 3,605 +30.0%
Interest Paid 2,739 3,227 -15.1%
Interest Paid Received Interest Rate Hedges 140 178 -21.3%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 41 -66 +162.1%
Net Change in Cash 91 -1,810 +105.0%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 1,197 1,107 +8.1%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key